Continuous positive airway pressure (CPAP) therapy has been the standard treatment for moderate-to-severe obstructive sleep apnoea for several decades. The story of CPAP, despite its clinical effectiveness when used, has been a story of adherence — patients prescribed CPAP often don’t use their devices consistently, and the gap between prescribed adherence and actual adherence has been a clinical concern for as long as the therapy has been in routine use.

The data from Australian sleep clinics through 2024 and 2025 provides a useful update on where adherence stands and what’s driving the variation.

What the numbers show

Among Australian patients prescribed CPAP through public and private sleep services in the two years to early 2026:

Approximately 65-72% of patients meet basic adherence thresholds (4+ hours per night on 70%+ of nights) at the 90-day mark. This is broadly consistent with international benchmarks and represents modest improvement from the figures published in the 2018-2019 period.

By the 12-month mark, the figure typically drops to 55-65%, reflecting the well-documented pattern of declining adherence over time. The decline isn’t uniform — some patients establish strong long-term use, others abandon therapy within months — but the aggregate trajectory is downward.

The gap between formal adherence-criteria-met and clinically-meaningful use is real. A patient meeting the 4-hours-70%-of-nights threshold may still be sleeping a substantial portion of nights without therapy, and may not be achieving the cardiovascular and quality-of-life benefits that consistent therapy delivers.

What’s actually driving adherence

Several factors come through consistently in the adherence data and the clinical observations.

Mask fit. The single most modifiable factor. Patients with well-fitted masks adapted to their facial morphology and sleeping posture show meaningfully better adherence than patients struggling with mask issues. The investment in mask fitting and ongoing adjustment is well-justified by the adherence outcomes.

Comorbid conditions. Patients with concurrent anxiety disorders, claustrophobia, or significant nasal congestion have meaningfully lower adherence. Addressing the underlying conditions — sometimes pharmacological, sometimes behavioural — typically improves CPAP outcomes more than focusing on the CPAP itself.

Partner involvement. Patients whose sleeping partners are actively supportive of therapy show better adherence. The bedroom is a shared environment and the partner’s tolerance of CPAP equipment matters.

Education and ongoing support. Patients who receive structured education at therapy initiation, with scheduled follow-up over the first 90 days, show meaningfully better long-term adherence than patients given the equipment and effectively left to figure it out. The clinical model that combines initial titration with active 30-60-90 day follow-up produces the strongest outcomes.

Underlying severity. Patients with more severe untreated apnoea — particularly those with significant daytime symptoms or cardiovascular risk — tend to show better long-term adherence, presumably reflecting the strength of the perceived benefit.

What’s not making the difference people expect

A few interventions and beliefs that show less impact in the data than clinicians or patients sometimes expect.

Device features and bells and whistles. Premium device features — heated humidification, ramp settings, comfort modes — do help individual patients in specific situations but the population-level adherence effect of the premium-versus-basic device distinction is modest.

Auto-titrating versus fixed-pressure CPAP. For most patients, the auto-titration feature improves comfort but doesn’t dramatically change long-term adherence. For specific patient subgroups it matters more.

Telemetry-enabled adherence monitoring. The remote monitoring features that allow clinical teams to see actual usage data have helped clinicians intervene earlier with adherence issues. The patient-side experience of being monitored hasn’t shown the privacy concerns some predicted, and the clinical-side ability to intervene proactively has been generally positive.

Where Australian practice is shifting

Several practical shifts in Australian sleep medicine practice through 2024-2026.

More patient-centred initiation processes. The standard initiation process has shifted from a single titration appointment to a structured education and titration sequence over 2-4 weeks. The longer onboarding period produces better long-term outcomes but requires more clinical time.

Better integration with primary care. The handover from sleep medicine specialist to general practitioner for ongoing CPAP management has improved in several jurisdictions, with structured follow-up protocols that GPs can deliver competently.

Expansion of CBT-i. Cognitive behavioural therapy for insomnia, often used alongside CPAP for patients with concurrent insomnia, has expanded modestly through Australia. The combination is more effective than CPAP alone for the subgroup of OSA patients with significant insomnia comorbidity.

Re-emphasis on weight management. The clinical conversation about weight management as an adjunct to CPAP has been re-energised by the availability of GLP-1 agonists for selected patients. The interaction of effective weight management with OSA outcomes is significant for patients who can access and tolerate the medications.

The patients who do best

A practical summary, based on the clinical data, of what tends to characterise CPAP patients with the strongest long-term outcomes:

Initial good mask fit, with prompt response to early discomfort issues. Strong partner support and a sleeping environment that accommodates the equipment. Concurrent management of any contributing conditions (rhinitis, claustrophobia, comorbid anxiety). Engagement with the clinical team through the first 6-12 months, with proactive response to telemetry data. Realistic expectations — recognition that CPAP is a long-term therapy rather than a quick fix.

The patients who don’t do well tend to have one or more of: poor mask fit not promptly addressed, untreated comorbid conditions, isolated sleep environment without partner support, minimal contact with the clinical team after initiation, and either over-optimistic or excessively-pessimistic expectations.

The honest summary is that CPAP adherence in Australia in 2026 is workable but imperfect. The clinical model that delivers the best outcomes is high-touch, multidisciplinary, and well-resourced. Within the constraints of the Australian health system, the centres delivering that model are achieving substantially better outcomes than those running thinner clinical processes. The patient experience and the clinical outcomes both benefit when the investment is made.